Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
Public ClinicalTrials.gov record NCT00093964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.
Study identification
- NCT ID
- NCT00093964
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EMD Serono
- Industry
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Interventions
- Cilengitide 500 mg Drug
- Cilengitide 2000 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2004
- Primary completion
- Oct 27, 2005
- Completion
- Oct 20, 2010
- Last update posted
- Apr 15, 2019
2004 – 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3280 | — |
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Denise Damek | Aurora | Colorado | 80010 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Massachusetts | Worcester | Massachusetts | 01655 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Good Samaritan Hospital/Tri Health Hatton Center | Cincinnati | Ohio | 45206 | — |
| Baylor University Medical Center at Dallas | Dallas | Texas | 75246 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Vermont/Fletcher Allen Healthcare | Burlington | Vermont | 05401 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00093964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00093964 live on ClinicalTrials.gov.